Halozyme Therapeutics, Inc. ( HALO) - Key Metrics
HALO Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $4.10 | $1.96 | $2.05 | $2.02 |
| 2026Q1 | $3.19 | $1.27 | $1.52 | $1.49 |
| 2025Q4 | $3.84 | -$1.20 | $1.86 | $1.85 |
| 2025Q3 | $3.02 | $1.49 | $1.52 | $1.50 |
| 2025Q2 | $2.68 | $1.36 | $0.82 | $0.81 |
HALO Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | 9.98 |
| 2026Q1 | 0% | 12.72 |
| 2025Q4 | 0% | -14.02 |
| 2025Q3 | 0% | 12.31 |
| 2025Q2 | 0% | 9.56 |
HALO Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2026Q2 | 2.58% | 0% |
| 2026Q1 | 2.31% | 0% |
| 2025Q4 | 2.75% | 0% |
| 2025Q3 | 2.04% | 0% |
| 2025Q2 | 1.55% | 0% |
HALO
Price: $98.66
52 week price:
Payout Ratio Range:
Earnings Per Share: 3.38 USD
P/E Ratio: 30.12
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 402302
Ebitda: 127.5 millionMarket Capitalization: 11.6 billion